Hovione Technology announces Papillon DPI

April 15th, 2019

Hovione Technology, a specialist in development of innovative inhalation device technology, has announced today it has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler patented by inventor Dr. Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.


The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodatea single or double blister configuration, enabling ultra-affordable drug therapies at global scale.


Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.


Hovione Technology’s CEO Peter Villax said, "This is a strategic DPI development for Hovione Technology which emphasizes our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialization of this innovative blister DPI”. 


Hovione Technology has a co-promotional agreement with active pharmaceutical ingredient manufacturer Hovione and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.

Download:Full Press Release(138.43 KB)
Cookie Policy
This site uses cookies. When browsing the site, you are consenting its use.
Learn more
I understood